IMPORTANCE In locally advanced pancreatic cancer, the role of chemoradiotherapy is controversial and the efficacy of...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : JAMA
Health-related quality of life (HRQOL) in cancer research is critical to more comprehensively evaluate patients’...
Posté par : Pr. Franck BONNETAIN, ,
Nom de la revue : Journal of Clinical Oncology
AbstractBackground: Health-related quality of life (HRQoL) is recognized as a component endpoint for cancer...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : BMC Cancer
Background: Deficient mismatch repair (dMMR) colon cancer (CC) is reportedly resistant to 5-fluorouracil (5FU) adjuvant...
Posté par : , Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : JNCI Journal of the National Cancer Institure
AbstractBACKGROUND:We investigated whether the health-related quality of life (HRQoL) score is a prognostic factor for...
Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : EJC
Purpose Eastern Cooperative Oncology Group Performance Status (ECOG-PS) is currently an important parameter in the...
Posté par : Pr. Franck BONNETAIN
Nom de la revue : Quality of Life Research
AbstractPURPOSE:The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant...
Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : JCO
AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...
Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Lancet Oncol
Abstract Background: Baseline prognostic biomarkers stratifying treatmentstrategies in first-line metastatic...
Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue :
BACKGROUND:A randomized multicenter phase II trial was conducted to assess the sequential treatment strategy using...
Posté par : Pr. Franck BONNETAIN, , Dr. Sophie PAGET-BAILLY
Nom de la revue : PlosOne
AbstractOverall survival (OS) has been considered as the most relevant primary endpoint but trials using OS often...
Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Expert Review of Anticancer Therapy